-
1
-
-
28544449847
-
Divergent immunoglobulin g subclass activity through selective Fc receptor binding
-
Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753):1510-1512
-
(2005)
Science
, vol.310
, Issue.5753
, pp. 1510-1512
-
-
Nimmerjahn, F.1
Ravetch, J.V.2
-
2
-
-
42949157368
-
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
-
Musolino A et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical effi cacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26(11):1789-1796
-
(2008)
J Clin Oncol
, vol.26
, Issue.11
, pp. 1789-1796
-
-
Musolino, A.1
-
3
-
-
0642373290
-
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
-
Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947
-
(2003)
J Clin Oncol
, vol.21
, Issue.21
, pp. 3940-3947
-
-
Weng, W.K.1
Levy, R.2
-
4
-
-
33646352962
-
Potent antibody therapeutics by design
-
Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 343-357
-
-
Carter, P.J.1
-
5
-
-
35748949531
-
Optimizing engagement of the immune system by anti-tumor antibodies: An engineer's perspective
-
Desjarlais JR et al (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 12(21-22):898-910
-
(2007)
Drug Discov Today
, vol.12
, Issue.21-22
, pp. 898-910
-
-
Desjarlais, J.R.1
-
6
-
-
0028920695
-
Recognition sites on human IgG for Fc gamma receptors: The role of glycosylation
-
Jefferis R, Lund J, Goodall M (1995) Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation. Immunol Lett 44(2-3):111-117
-
(1995)
Immunol Lett
, vol.44
, Issue.2-3
, pp. 111-117
-
-
Jefferis, R.1
Lund, J.2
Goodall, M.3
-
7
-
-
0030470557
-
Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor i and influence the synthesis of its oligosaccharide chains
-
Lund J et al (1996) Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 157(11): 4963-4969
-
(1996)
J Immunol
, vol.157
, Issue.11
, pp. 4963-4969
-
-
Lund, J.1
-
8
-
-
67649394336
-
Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action
-
Jefferis R (2009) Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30(7): 356-362
-
(2009)
Trends Pharmacol Sci
, vol.30
, Issue.7
, pp. 356-362
-
-
Jefferis, R.1
-
9
-
-
0035794194
-
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R
-
Shields RL et al (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591-6604
-
(2001)
J Biol Chem
, vol.276
, Issue.9
, pp. 6591-6604
-
-
Shields, R.L.1
-
10
-
-
33645218704
-
Engineered antibody Fc variants with enhanced effector function
-
Lazar GA et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103(11):4005-4010
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, Issue.11
, pp. 4005-4010
-
-
Lazar, G.A.1
-
11
-
-
0036670565
-
Engineering therapeutic antibodies for improved function
-
Presta LG et al (2002) Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30(4):487-490
-
(2002)
Biochem Soc Trans
, vol.30
, Issue.4
, pp. 487-490
-
-
Presta, L.G.1
-
12
-
-
34548770705
-
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors
-
Stavenhagen JB et al (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 67(18): 8882-8890
-
(2007)
Cancer Res
, vol.67
, Issue.18
, pp. 8882-8890
-
-
Stavenhagen, J.B.1
-
13
-
-
58149510052
-
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors
-
Sazinsky SL et al (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A 105(51):20167-20172
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.51
, pp. 20167-20172
-
-
Sazinsky, S.L.1
-
14
-
-
0035865063
-
Engineered antibodies with increased activity to recruit complement
-
Idusogie EE et al (2001) Engineered antibodies with increased activity to recruit complement. J Immunol 166(4):2571-2575
-
(2001)
J Immunol
, vol.166
, Issue.4
, pp. 2571-2575
-
-
Idusogie, E.E.1
-
15
-
-
80054839351
-
Combined Fc-proteinand Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
-
Repp R et al (2011) Combined Fc-proteinand Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods 373(1-2):67-78
-
(2011)
J Immunol Methods
, vol.373
, Issue.1-2
, pp. 67-78
-
-
Repp, R.1
-
16
-
-
0034717212
-
Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments
-
Boel E et al (2000) Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 239(1-2):153-166
-
(2000)
J Immunol Methods
, vol.239
, Issue.1-2
, pp. 153-166
-
-
Boel, E.1
-
17
-
-
84867835452
-
Fc engineering: Design, expression, and functional characterization of antibody variants with improved effector function
-
Derer S et al (2012) Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function. Methods Mol Biol 907:519-536
-
(2012)
Methods Mol Biol
, vol.907
, pp. 519-536
-
-
Derer, S.1
-
18
-
-
0031014785
-
IgG effector mechanisms
-
Clark MR (1997) IgG effector mechanisms. Chem Immunol 65:88-110
-
(1997)
Chem Immunol
, vol.65
, pp. 88-110
-
-
Clark, M.R.1
-
20
-
-
76249100176
-
Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells
-
Jung ST et al (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A 107(2):604-609
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, Issue.2
, pp. 604-609
-
-
Jung, S.T.1
-
21
-
-
79955019213
-
Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus
-
Horton HM et al (2011) Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol 186(7):4223-4233
-
(2011)
J Immunol
, vol.186
, Issue.7
, pp. 4223-4233
-
-
Horton, H.M.1
-
22
-
-
53349120501
-
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells
-
Richards JO et al (2008) Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 7(8):2517-2527
-
(2008)
Mol Cancer Ther
, vol.7
, Issue.8
, pp. 2517-2527
-
-
Richards, J.O.1
-
23
-
-
77953659426
-
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
-
Moore GL et al (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2(2):181-189
-
(2010)
MAbs
, vol.2
, Issue.2
, pp. 181-189
-
-
Moore, G.L.1
|